ARVN Company Profile and Key Details

Q: Who are the executives of ARVN?

Mr. Sean A. Cassidy C.P.A., CPA, M.B.A.Chief Financial Officer, Principal Financial Officer & TreasurerMr. Sean A. Cassidy CPA, CPA, M.B.A.Chief Financial Officer, Principal Financial Officer & TreasurerMs. Angela M. Cacace Ph.D.Senior Vice President of Neuroscience & Platform BiologyDr. John A. Grosso Ph.D.Senior Vice President of R&D Technical OperationsMr. Jeff BoyleVice President of Investor RelationsDr. Ian Taylor Ph.D.Chief Scientific OfficerDr. Ronald A. PeckChief Medical OfficerMr. Matthew Batters J.D.Gen. Counsel & Corporation Sec.Mr. David Loomis M.B.A.Vice President, Principal Accounting Officer & Chief Accounting OfficerDr. Randy Teel Ph.D.Senior Vice President of Corporation & Bus. Devel.Mr. Steve WeissSenior Vice President & Chief HR OfficerMr. David K. Loomis M.B.A.Vice President, Principal Accounting Officer & Chief Accounting OfficerDr. Ronald A. Peck M.D.Chief Medical OfficerDr. John G. Houston Ph.D.Chairperson, Chief Executive Officer & Pres

NASDAQ : ARVN

Arvinas

$8.31

0.02+0.24%

At Close 4:00 PM

67.69

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Arvinas, Inc. (ARVN) stock surged +0.24%, trading at $8.31 on NASDAQ, up from the previous close of $8.29. The stock opened at $8.25, fluctuating between $8.25 and $8.48 in the recent session.

Stock Snapshot

8.29

Prev. Close

536.17M

Market Cap

8.25

Day Low

-2.5

P/E Ratio

-3.32

EPS (TTM)

-5.74

Cash Flow per Share

8.25

Open

64.52M

Number of Shares

8.48

Day High

84.73%

Free Float in %

10.8

Book Value

469.2K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 30, 2026	8.25	8.48	8.25	8.31	519.38K
Jun 29, 2026	8.10	8.62	8.00	8.29	954.25K
Jun 26, 2026	8.13	8.26	7.83	8.00	3.03M
Jun 25, 2026	8.00	8.17	7.95	8.03	499.38K
Jun 24, 2026	8.00	8.48	7.97	8.05	675K
Jun 23, 2026	7.63	8.19	7.63	8.14	851.96K
Jun 22, 2026	7.70	7.76	7.48	7.74	711.05K
Jun 18, 2026	7.85	8.02	7.52	7.67	957.39K
Jun 17, 2026	7.45	7.86	7.45	7.67	567.75K
Jun 16, 2026	7.55	7.55	7.28	7.42	519.4K
Jun 15, 2026	7.66	7.83	7.38	7.49	575.6K
Jun 12, 2026	7.08	7.78	7.08	7.58	858.39K
Jun 11, 2026	6.99	7.25	6.97	7.09	817.43K
Jun 10, 2026	7.15	7.35	6.97	6.98	680.24K
Jun 09, 2026	7.22	7.37	7.01	7.21	981.34K
Jun 08, 2026	7.49	7.55	7.13	7.15	691.81K
Jun 05, 2026	7.71	7.81	7.40	7.42	649.13K
Jun 04, 2026	7.83	7.95	7.71	7.74	574.85K
Jun 03, 2026	7.88	7.94	7.56	7.70	1.23M
Jun 01, 2026	9.01	9.07	8.52	8.58	790.01K

Contact Details

New Haven, CT 06511

United States

https://www.arvinas.com 203 535 1456

About Company

Arvinas, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to identifying, advancing, and marketing innovative therapies designed to eliminate disease-causing proteins. The company's pipeline features several promising candidates. These include Bavdegalutamide, a proteolysis targeting chimera (PROTAC) protein degrader, currently in Phase I clinical trials, which specifically targets the androgen receptor (AR) protein to treat metastatic castration-resistant prostate cancer (mCRPC) in men. Another key PROTAC protein degrader is ARV-471, which targets the estrogen receptor protein for patients suffering from metastatic ER-positive/HER2-negative breast cancer. Furthermore, Arvinas is developing ARV-766, an investigational orally bioavailable PROTAC protein degrader also aimed at treating mCRPC in men. The company has strategic alliances with major pharmaceutical entities including Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., and Bayer AG. Founded in 2013, Arvinas, Inc. is headquartered in New Haven, Connecticut.

Stock Peers

ARGX

15.31+1.68%

argenx SE$927.77 REGN

-8.27-1.31%

Regeneron Pharmaceuticals, Inc.$623.54 UTHR

-3.09-0.57%

United Therapeutics Corporation$541.83 MDGL

9.67+1.83%

Madrigal Pharmaceuticals, Inc.$536.95 VRTX

-2.92-0.58%

Vertex Pharmaceuticals Incorporated$496.73 KRYS

-6.48-1.71%

Krystal Biotech, Inc.$371.67 PRAX

-15.77-4.50%

Praxis Precision Medicines, Inc.$334.79 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 LGND

2.05+0.65%

Ligand Pharmaceuticals Incorporated$316.09 ALNY

7.51+2.56%

Alnylam Pharmaceuticals, Inc.$301.03

Frequently Asked Questions

What is the current Arvinas, Inc. (ARVN) stock price?

Arvinas, Inc. (NASDAQ: ARVN) stock price is $8.31 in the last trading session. During the trading session, ARVN stock reached the peak price of $8.48 while $8.25 was the lowest point it dropped to. The percentage change in ARVN stock occurred in the recent session was 0.24% while the dollar amount for the price change in ARVN stock was $0.02.

ARVN's industry and sector of operation?

The NASDAQ listed ARVN is part of Biotechnology industry that operates in the broader Healthcare sector. Arvinas, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ARVN?

Mr. Sean A. Cassidy C.P.A., CPA, M.B.A.
Chief Financial Officer, Principal Financial Officer & Treasurer
Mr. Sean A. Cassidy CPA, CPA, M.B.A.
Chief Financial Officer, Principal Financial Officer & Treasurer
Ms. Angela M. Cacace Ph.D.
Senior Vice President of Neuroscience & Platform Biology
Dr. John A. Grosso Ph.D.
Senior Vice President of R&D Technical Operations
Mr. Jeff Boyle
Vice President of Investor Relations
Dr. Ian Taylor Ph.D.
Chief Scientific Officer
Dr. Ronald A. Peck
Chief Medical Officer
Mr. Matthew Batters J.D.
Gen. Counsel & Corporation Sec.
Mr. David Loomis M.B.A.
Vice President, Principal Accounting Officer & Chief Accounting Officer
Dr. Randy Teel Ph.D.
Senior Vice President of Corporation & Bus. Devel.
Mr. Steve Weiss
Senior Vice President & Chief HR Officer
Mr. David K. Loomis M.B.A.
Vice President, Principal Accounting Officer & Chief Accounting Officer
Dr. Ronald A. Peck M.D.
Chief Medical Officer
Dr. John G. Houston Ph.D.
Chairperson, Chief Executive Officer & Pres

How ARVN did perform over past 52-week?

ARVN's closing price is 37.13% higher than its 52-week low of $6.06 where as its distance from 52-week high of $14.51 is -42.73%.

How many employees does ARVN have?

Number of ARVN employees currently stands at 430.

Link for ARVN official website?

Official Website of ARVN is: https://www.arvinas.com

How do I contact ARVN?

ARVN could be contacted at phone 203 535 1456 and can also be accessed through its website. ARVN operates from 5 Science Park, New Haven, CT 06511, United States.

How many shares of ARVN are traded daily?

ARVN stock volume for the day was 469.2K shares. The average number of ARVN shares traded daily for last 3 months was 885.79K.

What is the market cap of ARVN currently?

The market value of ARVN currently stands at $536.17M with its latest stock price at $8.31 and 64.52M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	430
Beta	1.75
Sales or Revenue	$78.50M
5Y Sales Change%	-0.07%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	430
Beta	1.75
Sales or Revenue	$78.50M
5Y Sales Change%	-0.07%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ARVN Company Profile and Key Details

Arvinas

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Key Takeaways

Price Forecast & Outlook